rs2246709 — CYP3A4

CYP3A4's Hidden Intronic Variable — The rs2246709 Variant

CYP3A4 is the single most important drug-metabolizing enzyme in the human body, responsible for clearing approximately 50% of all prescription medications. Located in liver and intestinal cells, this cytochrome P450 enzyme¹¹ cytochrome P450 enzyme
A superfamily of oxidative enzymes that metabolize drugs, steroid hormones, and environmental toxins processes everything from statins and immunosuppressants to opioids, anticoagulants, and chemotherapy. The rs2246709 variant sits deep within an intron of CYP3A4 — not in the protein-coding sequence — yet accumulating clinical data suggest it meaningfully alters how efficiently the enzyme clears certain drugs.

The Mechanism

rs2246709 is located at chromosome 7, position 99,768,096 (GRCh38), within intron 8 of CYP3A4 (transcript notation: NM_001202855.3:c.670+258T>C²² NM_001202855.3:c.670+258T>C
Intronic variant 258 base pairs downstream of exon 8, using minus-strand coding notation; plus-strand genomic is NC_000007.14:g.99768096A>G). The reference allele on the plus strand is A; the alternate (risk) allele is G. Because CYP3A4 is encoded on the minus strand, the A>G change on the plus strand corresponds to T>C in the transcript.

Intronic variants influence gene function through several mechanisms: mRNA splicing regulation³³ mRNA splicing regulation
Intronic sequences contain splice enhancers and silencers that guide the spliceosome in joining exons; mutations can alter splice site selection or efficiency, cryptic splice site activation⁴⁴ cryptic splice site activation
An intronic mutation can create a new, competing splice donor or acceptor that inserts partial intron sequence into the mRNA, altered mRNA secondary structure, and tagging of functional haplotypes elsewhere in the gene. While the precise molecular mechanism of rs2246709 has not been conclusively characterized in published literature, its consistent association with drug clearance phenotypes across several independent clinical cohorts suggests a genuine, if modest, functional impact on CYP3A4 expression or activity.

One 2025 drug-drug interaction study using machine learning on CYP3A4 polymorphisms hypothesized that rs2246709 G>A represents a mutation that enhances enzyme activity⁵⁵ hypothesized that rs2246709 G>A represents a mutation that enhances enzyme activity
This framing used population-level machine learning and was not confirmed by in vitro assay, while the methadone pharmacokinetics study found G allele carriers had decreased CYP3A4 clearance. The discrepancy may reflect population context (Asian vs. mixed cohorts) or different substrate-specific effects. The weight of clinical evidence leans toward the G allele being associated with reduced CYP3A4 function.

The Evidence

The most precise pharmacokinetic evidence comes from a pediatric methadone study: Aruldhas et al., 2021⁶⁶ Aruldhas et al., 2021
"Pharmacokinetic Modeling of R and S-Methadone and Their Metabolites to Study the Effects of Various Covariates in Post-operative Children," CPT Pharmacometrics & Systems Pharmacology identified rs2246709 as a significant covariate, with the intronic variant associated with decreased clearance of both the R- and S-enantiomers of methadone. Methadone is heavily CYP3A4-dependent, making this a useful in-vivo pharmacokinetic probe.

In transplantation medicine, Wang et al., 2021⁷⁷ Wang et al., 2021
"Association of Polymorphism of CYP3A4, ABCB1, ABCC2, ABCG2, NFKB1, POR, and PXR with the Concentration of Cyclosporin A in Allogeneic Haematopoietic Stem Cell Transplantation Recipients," Xenobiotica found rs2246709 significantly associated with intravenous cyclosporin A trough concentrations (p = 0.015) in 40 transplant patients. Cyclosporin A is a narrow-therapeutic-index immunosuppressant whose blood levels must be maintained in a tight range — too low risks graft rejection, too high risks nephrotoxicity. A genetic factor that alters its clearance has direct clinical consequences.

For anticoagulation, Li et al., 2024⁸⁸ Li et al., 2024
"Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation," Cardiovascular Drugs and Therapy examined 165 non-valvular atrial fibrillation patients on rivaroxaban and found rs2246709 polymorphism status to be an independent risk factor for minor bleeding (p = 0.036). Rivaroxaban is metabolized partly by CYP3A4; impaired clearance raises drug exposure and anticoagulant effect.

In oncology, Gézsi et al., 2015⁹⁹ Gézsi et al., 2015
"In interaction with gender a common CYP3A4 polymorphism may influence the survival rate of chemotherapy for childhood acute lymphoblastic leukemia," Pharmacogenomics Journal found significant associations between rs2246709 and chemotherapy survival rates in 511 children with ALL, with a notable gender-by-genotype interaction. Risk assessment models incorporating this interaction outperformed standard clinical risk stratification at every evaluated time point.

Practical Actions

The G allele at rs2246709 is associated with reduced CYP3A4 clearance of certain substrates. Clinically, this means drugs that depend on CYP3A4 for elimination may accumulate to higher levels than expected at standard doses. The most important affected drug classes include:

• Opioid analgesics: methadone clearance is reduced; dose adjustment and closer monitoring for sedation/respiratory depression warranted
• Immunosuppressants: cyclosporin A and likely tacrolimus reach higher trough concentrations; therapeutic drug monitoring is especially important
• Anticoagulants: rivaroxaban levels may be elevated, increasing bleeding risk; particularly relevant for patients on chronic anticoagulation
• Statins: atorvastatin and simvastatin are CYP3A4 substrates; reduced clearance may increase myopathy risk
• Benzodiazepines and calcium channel blockers: midazolam, alprazolam, amlodipine, and diltiazem all undergo significant CYP3A4 metabolism

Note that the evidence for rs2246709 is at the moderate level — consistently replicated in several independent cohorts but not yet incorporated into clinical pharmacogenomics guidelines (CPIC or DPWG). Unlike the firmly established CYP3A4*22 variant (rs35599367), which shows 20–30% reduced activity with clear clinical guidance, rs2246709 lacks formal guideline review.

Interactions

CYP3A4*22 (rs35599367): The *22 allele is the most actionable CYP3A4 variant with established reduced function (~50% reduced mRNA expression) and near-clinical pharmacogenomics support. A person carrying both rs2246709-G and CYP3A4*22 would likely have compound reduction in CYP3A4 activity, with the *22 allele expected to be dominant. Combined recommendation would be to treat as a reduced-function CYP3A4 metabolizer with heightened monitoring for all narrow-therapeutic-index CYP3A4 substrates.

CYP3A5*1 (rs776746): CYP3A5 is co-expressed with CYP3A4 in liver and intestine, and CYP3A5 expressers (those with at least one CYP3A5*1 allele) have substantially elevated total CYP3A capacity. If someone carries both rs2246709-G (reduced CYP3A4) and CYP3A5*1 (increased CYP3A5), the CYP3A5 upregulation may partially compensate for reduced CYP3A4 clearance, particularly for tacrolimus. This interaction is especially relevant in African populations, where CYP3A5 expression is common.

CYP3A4*1B (rs2740574): This promoter variant is in moderate linkage disequilibrium with rs2246709 in some populations. Both affect CYP3A4 expression; their combined effect on drug metabolism has not been independently characterized.